MagQu Co., Ltd. launches new products for assaying amyloid beta and total tau proteins in human plasma for assessing Alzheimer's disease. The assay kits have been approved for clinical uses not only by Taiwan FDA but also CE IVD. Instead of lumbar puncture, the blood testing shows low risk and high convenience. The clinical sensitivity and specificity of finding amnestic mild cognitive impairment and early-stage Alzheimer’s disease are higher than 80%. The blood testing is a powerful screen for finding Alzheimer's disease at very early stage. With suitable interventions, the progression of disease could be delayed or terminated. In addition, the blood test is adequate for routine tests for well managing Alzheimer’s disease or monitoring the treatment effects. Currently, there are more than 100 hospitals and clinics in Taiwan are using such blood testing for high-risk population of Alzheimer’s disease. The blood test is also helpful to pharmaceutical companies to develop drugs for Alzheimer’s disease.